VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - FINANCIALPOST.COM - A La Une - 03/Sep 20:34
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone […]
Articles similaires
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia
pharmabiz.com - 13/Sep 16:48
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia
pharmabiz.com - 13/Sep 16:48
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes
financialpost.com - 09/Sep 16:02
VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...
Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes
financialpost.com - 09/Sep 16:02
VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...
First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
drugs.com - 05/Sep 04:09
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
financialpost.com - 13/Sep 12:38
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
financialpost.com - 13/Sep 12:38
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
financialpost.com - 14:56
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com...
Les derniers communiqués
-
Four Seasons to Expand Saudi Arabian Portfolio Alongside Dar Al Omran Company with New Hotel in Madinah
Four Seasons Hotels and Resorts - 07/05/2024
-
Four Seasons Yachts Unveils Inaugural Itineraries to the Caribbean and Mediterranean and a First Look at its 95 Spectacular Suites
Four Seasons Hotels and Resorts - 27/03/2024
-
Visual 01Elevating Excellence: Four Seasons Embarks on the Next Stage of Strategic Global Growth
Four Seasons Hotels and Resorts - 22/01/2024